The peptide safety and risks article covers the full spectrum of safety considerations, from sterile technique to recognizing adverse reactions
In this study, we examined changes in muscle mass and strength among elderly type 2 diabetes patients using Semaglutide, aiming to provide evidence-based guidance for its clinical application
The beyond-use date indicates the last day the medication should be used to ensure its safety and effectiveness
Adequate hydration is equally critical, especially when using bulk-forming laxatives or increasing dietary fibre
Over 26 weeks, participants receiving semaglutide experienced greater reductions in several alcohol-related measures than those receiving placebo
Other diabetes medication classes offer alternatives if GLP-1 therapy proves unsuitable: SGLT2 inhibitors (such as dapagliflozin or empagliflozin) provide cardiovascular and renal benefits without affecting gastric emptying, though require adequate renal function and carry risks of genital infections and diabetic ketoacidosis DPP-4 inhibitors (such as sitagliptin) work on the incretin system but with less pronounced gastrointestinal effects note these should not be combined with GLP-1 receptor agonists Traditional agents including metformin, sulfonylureas, or insulin may be appropriate depending on individual circumstances Any medication change should be made in consultation with your diabetes specialist or GP, considering your overall glycaemic control, cardiovascular risk profile, and treatment goals, in line with NICE NG28 guidance
